Price$16.22-3.12 (-16.13%)
2026-01-212026-04-24
News · 26 weeks31-94%
2025-11-022026-04-26
Mix2390d
- Insider14(61%)
- Other3(13%)
- Earnings3(13%)
- SEC Filings3(13%)
Latest news
25 items- PRStevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter 2026 on Thursday, May 7, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Thursday, May 7, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registrat
- INSIDERSEC Form 3 filed by new insider Santel Luciano3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Magistretti Elisabetta3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Flynn Karen3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Federici William J3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Spinazzi Alvise3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Morel Donald E Jr3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stevanato Franco3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Stevanato Sergio3/A - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lin Sue-Jean3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Balachandran Madhavan3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stevanato Sergio3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by Stevanato Group S.p.A.3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by Stevanato Group S.p.A.3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by Stevanato Group S.p.A.3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- PRStevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare ForumStevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Healthcare Forum taking place on Tuesday, March 17 and Wednesday, March 18, 2026. The Company will present on Tuesday, March 17, at 9.45-10.20 a.m. (ET). A live webcast will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event. About Stevanato Group Founded in 1949, Stevanato Group is a leading
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 20-F filed by Stevanato Group S.p.A.20-F - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- PRStevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins- Establishes Fiscal 2026 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025. Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods) For the fourth quarter of 2025, revenue increased 5% (7% on a constant currency basis) to €346.5 million, and high-value solutions represented 49% of total revenue. Gross profit margin increased 120 basis points to 30.9%, and adjusted EBITDA margin increased 70 basis points to 28.2%, for the fourth
- PRStevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 4, 2026, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Wednesday, March 4, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its web
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
STVN FAQ
7 questionsWhat does Stevanato Group S.p.A. do?
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.Where does STVN stock trade?
Stevanato Group S.p.A. (STVN) is listed on NYSE.What sector and industry is STVN in?
Stevanato Group S.p.A. operates in the Health Care sector, Medical/Dental Instruments industry.When did Stevanato Group S.p.A. go public?
Stevanato Group S.p.A. (STVN) completed its IPO in 2021.What are analysts saying about STVN?
Stevanato Group S.p.A. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $2400.00 price target on 2025-12-02. Recent price targets range from $2300.00 to $3400.00.What companies are similar to STVN?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare STVN side-by-side with any of them on Quantisnow.How can I track STVN on Quantisnow?
Quantisnow aggregates Stevanato Group S.p.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STVN to receive live email and push alerts on every new disclosure.